Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
Become a Member | Sign in
Home>News>This Article

SymBio Initiates Japanese Phase I Trial of Oral Rigosertib (SyB C-1101) in Frontline MDS

Published: Thursday, July 25, 2013
Last Updated: Thursday, July 25, 2013
Bookmark and Share
U.S. FDA has granted orphan drug designation for the use of rigosertib in MDS.

SymBio Pharmaceuticals Limited has announced that it commenced enrollment of its Phase I clinical trial for oral rigosertib (SyB C-1101) in frontline myelodysplastic syndrome (MDS) patients in Japan.

Under the terms of the license agreement concluded with Onconova Therapeutics, Inc. in July, 2011, SymBio has an exclusive license to develop and commercialize rigosertib in Japan and Korea. Rigosertib is a novel, patent protected inhibitor of PI3-kinase and PLK pathways in cancer cells.

MDS patients often require frequent blood transfusions due to the development of severe anemia (decrease in number of red blood cells), with a high rate of progression to acute myelogenous leukemia (AML). There are an estimated 11,000 MDS patients in Japan alone.

Currently there is no approved drug for patients who have experienced drug failure after frontline treatment of MDS using hypomethylating agents, and there is an urgent need to develop new therapies for the treatment of both relapsed/refractory (r/r) and frontline MDS.

Onconova Therapeutics, Inc. is currently conducting late stage clinical trials with rigosertib (ON 01910.Na) in the U.S. and Europe for the treatment of hematologic malignancies and solid tumors.

A pivotal trial in r/r MDS is underway using the intravenous (IV) formulation of rigosertib (SyB L-1101).

The U.S. FDA has granted orphan drug designation for the use of rigosertib in MDS, and has agreed to a Special Protocol Assessment (SPA) for this Phase III trial.

A pair of Phase II trials are underway in the U.S. for development of the oral formulation of rigosertib as frontline treatment for lower-risk MDS.

In addition to SymBio’s Phase I trial with oral rigosertib in frontline MDS, a Phase I trial in r/r MDS patients using the IV formulation of the drug is also underway in Japan.

SymBio is developing rigosertib expeditiously, shortening development time and making this innovative drug available to MDS patients in need.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

CTN Accepted for SymBio’s Japan Phase 1 Trial of Rigosertib (SyB L-1101)
U.S. FDA grants orphan drug designation for using rigosertib in MDS and pancreatic cancer.
Thursday, September 27, 2012
Scientific News
Drug May Prevent Life-Threatening Muscle Loss in Advanced Cancers
New data describes how an experimental drug can stop life-threatening muscle wasting (cachexia) associated with advanced cancers and restore muscle health.
Chemical Design Made Easier
Rice University scientists prepare elusive organocatalysts for drug and fine chemical synthesis.
Nanocarriers May Carry New Hope for Brain Cancer Therapy
Berkeley lab researchers develop nanoparticles that can carry therapeutics across the brain blood barrier.
Potential Persistent Tuberculosis Treatment
Researchers have discovered several first-in-class compounds that target hidden TB infections by attacking a critical process the bacteria use to survive in the hostile environment of the lungs.
Shedding Light on “Dark” Cellular Receptors
UNC and UCSF labs create a new research tool to find homes for two orphan cell-surface receptors, a crucial step toward finding better therapeutics and causes of drug side effects.
Giant Molecules Inhibit Ebola Infection
European researchers have designed a "giant" molecule formed by thirteen fullerenes covered by carbohydrates which, by blocking this receptor, are able to inhibit the cell infection by an artificial ebola virus model.
First Therapy Appearing to Reverse Decline in Parkinson’s
An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small clinical trial, say researchers at Georgetown University Medical Center (GUMC).
Fighting Pain with Ketamine
Researchers at the Texas A&M Health Science Center are using ketamine, a drug that already exists as an anesthetic, to treat pain.
Possible New Treatment for Neurodegenerative Diseases Found
Researchers at the University of Liverpool have found that a well-established anti-epileptic drug could also be used as a treatment for neurodegenerative diseases.
Breast Cancer Drug Beats Superbug
Tamoxifen helps white blood cells clear multidrug-resistant bacteria in lab and mouse studies.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos